Is Eltrombopag/Eltrombopag available in China?

Eltrombopag/Eltrombopag was released in2018year1It was approved for marketing in China on April 4 for the treatment of primary immune thrombocytopenia (ITP). Currently, Eltrombopag/Eltrombopag has been approved by more than 100 countries around the world for chronic immune (idiopathic) thrombocytopenic purpura (ITP has also been approved by 43 countries for the treatment of thrombocytopenia in patients with chronic hepatitis C (CHC). However, like all drugs, Eltrombopag may also cause some side effects and risks, including but not limited to headache, nausea, abdominal pain, etc. For patients who use this drug, doctors will weigh the pros and cons based on the patient's specific situation and formulate the most appropriate treatment plan.